• TechCrunch
• CrunchBase
• More
  • TechCrunch Europe
  • TechCrunch France
  • TechCrunch Japan

Artisan Pharma

edit

Artisan Pharma, Inc., a biopharmaceutical company, provides critical-care and hospital-based therapeutics to patients, treating physicians, and payors in the United States and internationally. It offers ART-123, a novel, recombinant, and soluble thrombomodulin for the treatment of disseminated intravascular coagulation in sepsis. The company offers its products in Japan, China, Taiwan, and Korea. It has a strategic manufacturing alliance with A-Bio Pharma Pte Ltd. Artisan Pharma, Inc. was formerly known as Artisan Therapeutics, Inc. and changed its name to Artisan Pharma, Inc. in September 2006. The company was founded in 2006 and is headquartered in Waltham, Massachusetts.

Milestones

edit

• 
  Artisan Pharma added Jeffrey D. Wager as CEO.
  Posted 1/20/10 at 10:42pm
• 
  Artisan Pharma received $3M in Series C funding. (7/20/10)
  Posted 10/31/10 at 10:03pm via masshightech.com
• 
  Artisan Pharma received $22M in Series B funding. (3/1/10)
  Posted 7/20/10 at 6:04pm via artisanpharma.net
• 
  Artisan Pharma received $39M in Series A funding. (9/6/06)
  Posted 4/20/10 at 3:44am via artisanpharma.net
• 
  Artisan Pharma received $6M in Debt funding. (1/20/10)
  Posted 1/20/10 at 10:42pm via masshightech.com

Videos

Screenshots

edit

Above: Home Page
Uploaded: 1/21/10

Sources

1. Artisan Pharma, Inc. Raises $39 Million in a Series A Financing Led by NGN Capital LLC (artisanpharma.net) [edit]
2. Artisan Pharma collects $6M (masshightech.com) [edit]
3. Artisan Pharma Raises $22 Million Series B Financing (artisanpharma.net) [edit]
4. Artisan Pharma adds $3M to coffers in new round (masshightech.com) [edit]